| Code | CSB-RA006595MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to PRTH-101, targeting Discoidin Domain Receptor 1 (DDR1), a receptor tyrosine kinase that binds to various collagens in the extracellular matrix. DDR1 plays a critical role in cell adhesion, migration, proliferation, and extracellular matrix remodeling through collagen-mediated signaling pathways. Aberrant DDR1 expression and activation have been implicated in multiple pathological conditions, including fibrotic diseases, tumor progression, and metastasis. Elevated DDR1 levels are observed in various cancers, including lung, breast, ovarian, and brain malignancies, where it contributes to tumor cell invasion, epithelial-mesenchymal transition, and resistance to therapy.
PRTH-101 is an anti-DDR1 monoclonal antibody, designed to block the DDR1 signaling pathway activated by collagen, thereby inhibiting tumor growth, invasion, and metastasis, and possibly improving the tumor microenvironment and enhancing the efficacy of other therapies. It is currently in the preclinical/early clinical stage and is being explored for the treatment of solid tumors ( e.g. triple-negative breast cancer, pancreatic cancer, liver cell carcinoma) and fibrotic diseases. This biosimilar provides researchers with a valuable tool for investigating DDR1-mediated mechanisms in cancer biology, fibrosis, and tissue remodeling processes. It supports studies examining collagen receptor signaling, tumor microenvironment interactions, and potential therapeutic interventions targeting DDR1 pathways in preclinical disease models.
There are currently no reviews for this product.